The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Open accessAbstract
Cancer-associated IDH mutations are characterized by neomorphic enzyme activity and resultant 2-hydroxyglutarate (2HG) production. Mutational and epigenetic profiling of a large acute myeloid leukemia (AML) patient cohort revealed that IDH1/2-mutant AMLs display global DNA hypermethylation and a specific hypermethylation signature. Furthermore, expression of 2HG-producing IDH alleles in cells induced global DNA hypermethylation. In the AML cohort, IDH1/2 mutations were mutually exclusive with mutations in the α-ketoglutarate-dependent enzyme TET2, and TET2 loss-of-function mutations were associated with similar epigenetic defects as IDH1/2 mutants. Consistent with these genetic and epigenetic data, expression of IDH mutants impaired TET2 catalytic function in cells. Finally, either expression of mutant IDH1/2 or Tet2 depletion impaired hematopoietic differentiation and increased stem/progenitor cell marker expression, suggesting a shared proleukemogenic effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [153]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistently, TET2-mutant immature and myeloid cells present with hypermethylation of active enhancers and perturbed TF activity (28, 32, 53).”
From PU.1-Dependent Enhancer Inhibition Separates Tet2 -Deficient Hematopoiesis from Malignant Transformation (2022) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [4]
In the citing paper
“As a result, D-2HG accumulation in cancer cells expressing mutant IDH results in hypermethylation of histones and CpG islands in DNA (Figueroa et al., 2010; Lu et al., 2012; Turcan et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Figueroa et al., 2010
In the citing paper
“Mutations in isocitrate dehydrogenase isoform-1 (IDH1) and IDH2 generate the oncometabolite D-2-hydroxyglutarate (D-2HG), which inhibits epigenetic enzymes including histone demethylases and the Ten-eleven translocation (TET) family of 5-methylcytosine hydroxylases.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [25]
In the citing paper
“These effects contribute to tumor initiation in acute myelogenous leukemia (AML) by resulting in persistent histone and DNA methylation and impaired cellular differentiation (25).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [25]
In the citing paper
“The role of R-2-HG as an oncometabolite has been implicated in epigenetic modifications through the inhibition of α-KG-dependent dioxygenases and demethylases”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [117]
In the citing paper
“In addition, TET2 inactivation is sufficient to promote hematopoietic stem cell self-renewal and to block differentiation (Figueroa et al., 2010; Li et al., 2011; Moran-Crusio et al., 2011; Noushmehr et al., 2010; Turcan et al., 2012; Losman et al., 2013).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“In this regard, TET2 and IDH mutations are both found in acute myelogenous leukemia and are mutually exclusive, consistent with the idea that R-2HG produced by mutant IDH provides an alterative means of inactivating TET2 (Figueroa et al., 2010).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“R-2HG, succinate, and fumarate are all capable of inhibiting multiple 2-oxoglutarate-dependent dioxygenases, including the JmjC histone demethylases and TET proteins, when present at sufficiently high concentrations (Figure 6B) (Cervera et al., 2009; Chowdhury et al., 2011; Figueroa et al., 2010; Koivunen et al., 2012; Lu et al., 2012; Smith et al., 2007; Turcan et al., 2012; Xiao et al., 2012; Xu”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“More recently, we have also learnt how the catalytic activity of EZH2 can be compromised by so called 'oncohistones' 100 (Figure 3).”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [100]
In the citing paper
“Around 30% of all paediatric glioblastomas contain mutations in histone genes resulting in H3K27M, H3K27I and H3G34V/R substitutions (reviewed in REF. 100 ).”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [100]
In the citing paper
“in a large acute myelogenous leukaemia (AML) cohort, TET2 was found to be mutually exclusive with gain-of-function mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 (REF.65).”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [65]
In the citing paper
“Heterozygous, inactivating ten-eleven translocation 2 (TET2) mutations and neomorphic isocitrate dehydrogenase (IDH) mutations are recurrent and mutually exclusive in acute myeloid leukaemia genomes.”
From Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia (2018) · cites this paper as [5]
In the citing paper
“By blocking the enzymatic activity of histone and DNA demethylases, d-2HG can function to lock cells in a hypermethylated state that blocks differentiation and reinforces a malignant and stem cell–like phenotype (30, 172, 173, 174).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [172]
In the citing paper
“Indeed, IDH-driven gliomas, leukemias and chondrosarcomas display a prominent CpG island hypermethylation, reminiscent of the hypermethylator phenotype seen in SDH- and FH-deficient cancers (Figueroa et al., 2010; Lu et al., 2013; Turcan et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Figueroa et al., 2010
In the citing paper
“IDH mutations in AML are mutually exclusive with inactivating mutations in TET2 methylcytosine hydroxylases, further implicating mutant IDH as a bona fide driver of epigenetic remodeling (Figueroa et al., 2010).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Figueroa et al., 2010
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
In the citing paper
“Mutant IDH2 [Arg140→Gln140 (R140Q)], which promotes α-KG depletion/2-HG production, promotes DNA hypermethylation in hematopoietic cells and can inhibit myeloid differentiation when overexpressed in bone marrow stem cells (79).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
In the citing paper
“multiple groups have found that IDH mutant expression and 2HG elevation can inhibit the TET family of enzymes that hydroxylate 5’-methylcytosine (Figueroa et al., 2010; Turcan et al., 2012; Xu et al., 2011)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“TET2 mutant AML samples displayed an overlapping DNA hypermethylation signature with samples having IDH1 or IDH2 mutations”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“neomorphic mutations of IDH1 or IDH2 and TET2 loss-of-function mutations were found to be mutually exclusive in a large AML cohort”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“In both cell types, the overexpression of IDH mutants blocked acquisition of mature myeloid markers while increasing the expression of stem cell markers (Figueroa et al., 2010).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“shRNA knockdown of TET2 recapitulated the effect of IDH mutant overexpression on blocking hematopoietic cell differentiation (Figueroa et al., 2010)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“mutations in IDH1/2 and in the 5-methylcytosine hydroxylase TET2 occur frequently in acute myelogenous leukemia”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“primary IDH1- or IDH2-mutant tumors showed evidence of extensively altered histone and DNA methylation in vivo”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“the mutations were found to be mutually exclusive”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“high concentrations of 2-HG inhibited the function of α-ketoglutarate-dependent histone demethylases and 5-methylcytosine hydroxylases in vitro”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“metabolomic profiling of mIDH1/2 gliomas revealed significant alterations in cellular metabolism, an effect recapitulated with the exogenous addition of D-2-HG134.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [134]
In the citing paper
“This metabolic rewiring resulted in a decrease in a common dipeptide found in the brain N-acetyl-aspartyl-glutamate (NAAG), and NAAG levels were found to be significantly lower in IDH-mutant human glioma tissue134.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationIto, S., D’Alessio, A. C., Taranova, O., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,628
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Histone demethylation by a family of JmjC domain-containing proteins
Tsukada, Y.-I., Fang, J., Erdjument‐Bromage, H., Warren, M., Borchers, C. H., Tempst, P., & Zhang, Y. (2005) · Nature · doi:10.1038/nature04433 · Cited by 2,171
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Self-citation
Flagged first, then by citations
1 of the 35 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 701–800 of 1,005
DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses
Dan, H., Zhang, S., Zhou, Y., & Guan, Q. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s217767 · Cited by 83
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Nwosu, G. O., Ross, D. M., Powell, J. A., & Pitson, S. M. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06810-7 · Cited by 80
Jeffery, C. J. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.10.003 · Cited by 83
Zhu, D., HUNTER, S. B., Vertino, P. M., & Meir, E. G. V. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1157 · Cited by 84
Update on rational targeted therapy in AML
Shafer, D. A., & Grant, S. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.02.001 · Cited by 79
Hou, H., & Tien, H. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00674-7 · Cited by 86
Mutant IDH1 Enhances the Production of 2-Hydroxyglutarate Due to Its Kinetic Mechanism
Rendina, A. R., Pietrak, B., Smallwood, A. M., Zhao, H., Qi, H., Quinn, C. J., Adams, N. D., Concha, N. O., Duraiswami, C., Thrall, S. H., et al. (2013) · Biochemistry · doi:10.1021/bi400514k · Cited by 81
Liang, D., Liu, H., Yang, C., Jaing, T., Hung, I., Yeh, T., Chen, S., Hou, J., Huang, Y., Shih, Y., et al. (2013) · Blood · doi:10.1182/blood-2012-06-436782 · Cited by 81
Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia
Quek, L. S., Ferguson, P., Metzner, M., Ahmed, I., Kennedy, A., Garnett, C., Jeffries, S., Walter, C. U., Piechocki, K., Timbs, A., et al. (2016) · Blood Advances · doi:10.1182/bloodadvances.2016000760 · Cited by 81
Weinstabl, H., Treu, M., Rinnenthal, J., Zahn, S. K., Ettmayer, P., Bader, G., Dahmann, G., Kessler, D., Rumpel, K., Mischerikow, N., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00718 · Cited by 79
Self-citationTargeting Metabolic Reprogramming in Acute Myeloid Leukemia
Castro, I., Sampaio‐Marques, B., & Ludovico, P. (2019) · Cells · doi:10.3390/cells8090967 · Cited by 79
2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter
Yang, Z., Jiang, B., Wang, Y., Ni, H., Zhang, J., Xia, J., Shi, M., Hung, L.-M., Ruan, J., Mak, T. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.012 · Cited by 78
Chromatin modifiers and the promise of epigenetic therapy in acute leukemia
Greenblatt, S. M., & Nimer, S. D. (2014) · Leukemia · doi:10.1038/leu.2014.94 · Cited by 83
Cancer: pathological nuclear reprogramming?
Goding, C. R., Pei, D., & Lü, X. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3781 · Cited by 82
Pérez, C., Martínez‐Calle, N., Martín-Subero, J. I., Segura, V., Delabesse, É., Fernández‐Mercado, M., Gárate, L., Álvarez, S., Rifón, J., Varea, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031605 · Cited by 78
JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
McKenney, A. S., Lau, A. N., Somasundara, A. V. H., Spitzer, B. G., Intlekofer, A. M., Ahn, J., SHANK, K. R., Rapaport, F. T., Patel, M. A., Papalexi, E., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94516 · Cited by 81
Self-citationVitamin C increases 5-hydroxymethylcytosine level and inhibits the growth of bladder cancer
Ding, P., Ge, G., Gong, Y., Zhan, Y., He, S., Guan, B., Li, Y., Xu, Z., Hao, H., He, Z., et al. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0527-7 · Cited by 78
Self-citationEmadi, A., Faramand, R. G., Carter‐Cooper, B., Tolu, S. S., Ford, L. A., Lapidus, R. G., Wetzler, M., Wang, E. S., Etemadi, A., & Griffiths, E. A. (2015) · American Journal of Hematology · doi:10.1002/ajh.23965 · Cited by 78
Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors
Schaap, F. G., French, P. J., & Bovée, J. V. M. G. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31827b654d · Cited by 80
Mason, E. F., & Hornick, J. L. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.86 · Cited by 78
Clinical significance of genetic aberrations in secondary acute myeloid leukemia
Feenstra, J. D. M., Puda, A., Malcovati, L., Berg, T., Hofbauer, M., Stukalov, A., Klampfl, T., Harutyunyan, A. S., Gisslinger, H., Gisslinger, B., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23309 · Cited by 84
Reconstructing the molecular life history of gliomas
Barthel, F. P., Wesseling, P., & Verhaak, R. G. W. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1842-y · Cited by 86
Normal Hematopoiesis Is a Balancing Act of Self-Renewal and RegenerationPreprint
Olson, O. C., Kang, Y.-A., & Passegue, E. A. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a035519 · Cited by 89
Elhammali, A., Ippolito, J. E., Collins, L., Crowley, J., Marasa, J., & Piwnica-Worms, D. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0572 · Cited by 77
Myelofibrosis in 2019: moving beyond JAK2 inhibition
Schieber, M., Crispino, J. D., & Stein, B. L. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0236-2 · Cited by 79
Targeting Metabolism to Induce Cell Death in Cancer Cells and Cancer Stem Cells
Pecqueur, C., Oliver, L., Oizel, K., Lalier-Bretaudeau, L., & Vallette, F. M. (2013) · International Journal of Cell Biology · doi:10.1155/2013/805975 · Cited by 83
Non-genotoxic carcinogen exposure induces defined changes in the 5-hydroxymethylome
Thomson, J. P., Lempiäinen, H., Hackett, J. A., Nestor, C. E., Müller, A., Bolognani, F., Oakeley, E. J., Schübeler, D., Terranova, R., Reinhardt, D., et al. (2012) · Genome biology · doi:10.1186/gb-2012-13-10-r93 · Cited by 77
Translational and clinical implications of the genetic landscape of prostate cancer
Spratt, D. E., Zumsteg, Z. S., Feng, F. Y.-C., & Tomlins, S. A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.76 · Cited by 78
Chromatin-modifying agents in anti-cancer therapy
Seidel, C., Florean, C., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2012) · Biochimie · doi:10.1016/j.biochi.2012.05.012 · Cited by 79
Immunometabolism orchestrates training of innate immunity in atherosclerosis
van Tuijl, J., Joosten, L. A. B., Netea, M. G., Bekkering, S., & Riksen, N. P. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz107 · Cited by 77
Metabolic determinants of tumour initiation
Brunner, J. S., & Finley, L. W. S. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00773-5 · Cited by 78
Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)
Wysota, M., Konopleva, M. Y., & Mitchell, S. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01503-y · Cited by 76
Genetic and epigenetic alterations of myeloproliferative disorders
Feenstra, J. D. M., & Královics, R. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1235-2 · Cited by 81
Fathi, A. T., Sadrzadeh, H., Comander, A. H., Higgins, M. J., Bardia, A., Perry, A. M., Burke, M. E., Silver, R. M., Matulis, C. R., Straley, K. S., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0417 · Cited by 77
Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1
Cahill, D. P., Louis, D. N., & Cairncross, J. G. (2015) · CNS Oncology · doi:10.2217/cns.15.32 · Cited by 77
TET2 binds the androgen receptor and loss is associated with prostate cancer
Nickerson, M. L., Das, S., Im, K. M., Turan, S., Berndt, S. I., Li, H., Lou, H., Brodie, S. A., Billaud, J.-N., Zhang, T., et al. (2016) · Oncogene · doi:10.1038/onc.2016.376 · Cited by 78
Li, H., Chawla, G., Hurlburt, A. J., Sterrett, M. C., Zaslaver, O., Cox, J. E., Karty, J. A., Rosebrock, A. P., Caudy, A. A., & Tennessen, J. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614102114 · Cited by 76
HDAC Inhibition to Prime Immune Checkpoint Inhibitors
Borcoman, E., Kamal, M., Marret, G., Dupain, C., Castel-Ajgal, Z., & Le Tourneau, C. (2021) · Cancers · doi:10.3390/cancers14010066 · Cited by 75
IDH3α regulates one-carbon metabolism in glioblastoma
May, J., Kouri, F. M., Hurley, L., Liu, J., Tommasini-Ghelfi, S., Ji, Y., Gao, P., Calvert, A. E., Lee, A., Chandel, N. S., et al. (2019) · Science Advances · doi:10.1126/sciadv.aat0456 · Cited by 76
Becker‐Kettern, J., Paczia, N., Conrotte, J., Kay, D. P., Guignard, C., Jung, P. P., & Linster, C. L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.704494 · Cited by 76
OH, the Places You’ll Go! Hydroxylation, Gene Expression, and Cancer
Ploumakis, A., & Coleman, M. L. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.026 · Cited by 77
5‐Hydroxymethylcytosine: a new kid on the epigenetic block?
Matarese, F., Pau, E. C. D. S., & Stunnenberg, H. G. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.95 · Cited by 77
TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations: Figure 1
Kim, Y.-H., Pierscianek, D., Mittelbronn, M. G. A., Vital, A., Mariani, L., Hasselblatt, M., & Ohgaki, H. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200133 · Cited by 74
Mitochondrial metabolism as a target for acute myeloid leukemia treatment
Panina, S., Pei, J., & Kirienko, N. V. (2021) · Cancer & Metabolism · doi:10.1186/s40170-021-00253-w · Cited by 74
Differentiation therapy for myeloid malignancies: beyond cytotoxicity
Stubbins, R. J., & Karsan, A. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00584-3 · Cited by 75
Virdi, K. S., Wamboldt, Y., Kundariya, H., Laurie, J. D., Keren, I., Kumar, K. R. S., Block, A. K., Basset, G. J. C., Luebker, S., Elowsky, C. G., et al. (2015) · Molecular Plant · doi:10.1016/j.molp.2015.10.011 · Cited by 74
Portraits of TET-mediated DNA hydroxymethylation in cancer
Jeschke, J., Collignon, É., & Fuks, F. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.01.004 · Cited by 76
Leisch, M., Jansko, B., Zaborsky, N., Greil, R., & Pleyer, L. (2019) · Cancers · doi:10.3390/cancers11020252 · Cited by 76
Mitochondria in cancer metabolism, an organelle whose time has come?
Anderson, R. G., Ghiraldeli, L. P., & Pardee, T. S. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.05.005 · Cited by 76
Isocitrate dehydrogenase mutations in leukemia
McKenney, A. S., & Levine, R. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67266 · Cited by 78
Self-citationMetabolic Mechanisms of Epigenetic Regulation
Meier, J. L. (2013) · ACS Chemical Biology · doi:10.1021/cb400689r · Cited by 75
5-hydroxymethylcytosine marks promoters in colon that resist DNA hypermethylation in cancer
Uribe‐Lewis, S., Stark, R., Carroll, T. D., Dunning, M., Bachman, M., Ito, Y., Stojic, L., Halim, S., Vowler, S. L., Lynch, A. G., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0605-5 · Cited by 75
Dnmt3a regulates both proliferation and differentiation of mouse neural stem cells
Wu, Z., Huang, K. Y., Yu, J., Le, T. T., Namihira, M., Liu, Y., Zhang, J., Xue, Z., Cheng, L., & Fan, G. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23077 · Cited by 76
Kurek, K. C., Pansuriya, T. C., van Ruler, M. A. J. H., van den Akker, B., Luks, V. L., Verbeke, S., Kozakewich, H. P., Sciot, R., Lev, D. C., Lazar, A. J., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.01.012 · Cited by 73
Heavy Metals and Epigenetic Alterations in Brain Tumors
Caffo, M., Caruso, G., Fata, G. L., Barresi, V., Visalli, M., Venza, M., & Venza, I. (2015) · Current Genomics · doi:10.2174/138920291506150106151847 · Cited by 74
Qu, J., Sun, W., Zhong, J., Lv, H., Zhu, M., Xu, J., Jin, N., Xie, Z., Tan, M., Lin, S., et al. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201607008 · Cited by 74
Nakagawa, M., Nakatani, F., Matsunaga, H., Seki, T., Endo, M., Ogawara, Y., Machida, Y., Katsumoto, T., Yamagata, K., Hattori, A., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0929-9 · Cited by 78
Epigenetics in T‐cell acute lymphoblastic leukemia
Peirs, S., der Meulen, J. V., de Walle, I. V., Taghon, T., Speleman, F., Poppe, B. G., & Vlierberghe, P. V. (2014) · Immunological Reviews · doi:10.1111/imr.12237 · Cited by 76
Investigational cancer drugs targeting cell metabolism in clinical development
Sborov, D. W., Haverkos, B. M., & Harris, P. J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.960077 · Cited by 72
Hydroxymethylation of DNA: an epigenetic marker.
Sinha, R. P., & Sinha, R. P. (2014) · Europe PMC (PubMed Central) · Cited by 72
Chen, Q., Yin, D., Zhang, Y., Yu, L., Li, X., Zhou, Z., Zhou, S., Gao, D., Hu, J., Jin, C. S., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.142 · Cited by 71
Wick, A., Bähr, O., Schüler, M., Rohrberg, K. S., Chawla, S. P., Jankú, F., Schiff, D., Heinemann, V., Narita, Y., Lenz, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4256 · Cited by 71
Biology of IDH mutant cholangiocarcinoma
Wu, M., Shi, L., Merritt, J., Zhu, A. X., & Bardeesy, N. M. (2022) · Hepatology · doi:10.1002/hep.32424 · Cited by 71
Chow, L. K.-Y., Chung, D. L., Tao, L., Chan, K. F., Tung, S. Y., Ngan, R. K., Ng, W. T., Lee, A. W. M., Yau, C. C., Kwong, D. L., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104357 · Cited by 71
Why methylation is not a marker predictive of response to hypomethylating agents
Voso, M. T., Santini, V., Fabiani, E., Fianchi, L., Criscuolo, M., Falconi, G., Guidi, F., Hohaus, S., & Leone, G. G. M. (2014) · Haematologica · doi:10.3324/haematol.2013.099549 · Cited by 73
Epigenetic dysregulation in glioma
Kondo, Y., Katsushima, K., Ohka, F., Natsume, A., & Shinjo, K. (2014) · Cancer Science · doi:10.1111/cas.12379 · Cited by 73
Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia
Li, M., Collins, R., Jiao, Y., Ouillette, P. D., Bixby, D. L., Erba, H. P., Vogelstein, B., Kinzler, K. W., Papadopoulos, N., & Malek, S. N. (2011) · Blood · doi:10.1182/blood-2011-05-356204 · Cited by 71
Visconte, V., Tiu, R. V., & Rogers, H. J. (2014) · Blood Research · doi:10.5045/br.2014.49.4.216 · Cited by 73
Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2
Borodovsky, A., Seltzer, M. J., & Riggins, G. J. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834d816a · Cited by 71
Bhattacharyya, S., Pradhan, K., Campbell, N. R., Mazdo, J., Vasantkumar, A., Maqbool, S. B., Bhagat, T. D., Gupta, S., Suzuki, M., Yu, Y., et al. (2017) · Genome Research · doi:10.1101/gr.222794.117 · Cited by 74
Self-citationMetabolic signatures of human breast cancer
Mishra, P., & Ambs, S. (2015) · Molecular & Cellular Oncology · doi:10.4161/23723556.2014.992217 · Cited by 70
Impact of Genetic Features on Treatment Decisions in AML
Döhner, H., & Gaidzik, V. I. (2011) · Hematology · doi:10.1182/asheducation-2011.1.36 · Cited by 72
DNA methylation and hydroxymethylation in hematologic differentiation and transformation
Ko, M., An, J., & Rao, A. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.009 · Cited by 71
Isocitrate dehydrogenase variants in cancer — Cellular consequences and therapeutic opportunities
Liu, S., Cadoux-Hudson, T. A. D., & Schofield, C. J. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.06.012 · Cited by 70
Differentiation therapy of myeloid leukemia: four decades of development
Madan, V., & Koeffler, H. P. (2020) · Haematologica · doi:10.3324/haematol.2020.262121 · Cited by 72
Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin
Griffin, G. K., Booth, C. A. G., Togami, K., Chung, S. S., Ssozi, D., Verga, J. A., Bouyssou, J., Lee, Y. S., Shanmugam, V., Hornick, J. L., et al. (2023) · Nature · doi:10.1038/s41586-023-06156-8 · Cited by 70
Lund, K., Cole, J. J., VanderKraats, N. D., McBryan, T., Pchelintsev, N. A., Clark, W. A., Copland, M., Edwards, J. R., & Adams, P. D. (2014) · Genome biology · doi:10.1186/s13059-014-0406-2 · Cited by 72
Qu, X., Zhang, S., Wang, S., Wang, Y., Li, W., Huang, Y., Zhao, H., Wu, X., An, C., Guo, X., et al. (2018) · Blood · doi:10.1182/blood-2018-05-853291 · Cited by 73
Urban, D. J., Martinez, N. J., Davis, M. I., Brimacombe, K. R., Cheff, D. M., Lee, T. D., Henderson, M. J., Titus, S. A., Pragani, R., Rohde, J. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12630-x · Cited by 71
Gopinathan, G., & Khosla, S. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-4525-4_26 · Cited by 71
Individualized Targeted Therapy for Glioblastoma
Weller, M., Stupp, R., Hegi, M. E., & Wick, W. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e318243f6c9 · Cited by 69
IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
Cerchione, C., Romano, A., Daver, N. G., Dinardo, C. D., Jabbour, E. J., Konopleva, M. Y., Ravandi‐Kashani, F., Kadia, T. M., Martelli, M. P., Isidori, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.639387 · Cited by 73
Miller, J. J. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01238-3 · Cited by 70
Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer
Bhattacharyya, S., Yu, Y., Suzuki, M., Campbell, N. R., Mazdo, J., Vasanthakumar, A., Bhagat, T. D., Nischal, S., Christopeit, M., Parekh, S. S., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt601 · Cited by 70
Self-citationAlsadoun, N., MacGrogan, G. M., Truntzer, C., Lacroix‐Triki, M., Bedgedjian, I., Koeb, M.-H., Alam, E. E., Médioni, D., Parent, M., Wuithier, P., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0047-1 · Cited by 69
DNA methylation/hydroxymethylation in melanoma
Fu, S., Wu, H., Zhang, H., Lian, C. G., & Lu, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.18293 · Cited by 70
The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
Nassereddine, S., Lap, C. J. G., Haroun, F., & Tabbara, I. A. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3161-0 · Cited by 69
Li, Z., Lyu, C., Ren, Y., & Wang, H. (2020) · Environmental Health Perspectives · doi:10.1289/ehp5862 · Cited by 68
TET Family of Dioxygenases: Crucial Roles and Underlying Mechanisms
Li, D., Guo, B., Wu, H., Tan, L., & Lu, Q. (2015) · Cytogenetic and Genome Research · doi:10.1159/000438853 · Cited by 74
Kreth, S., Thon, N., & Kreth, F. W. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.04.008 · Cited by 68
Ten Eleven Translocation Enzymes and 5-Hydroxymethylation in Mammalian Development and Cancer
Kinney, S. R. M., & Pradhan, S. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-9967-2_3 · Cited by 68
Epigenetic profiles as defined signatures of xenobiotic exposure
Thomson, J. P., Moggs, J. G., Wolf, C. R., & Meehan, R. R. (2013) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2013.08.007 · Cited by 70
Zhu, X., You, Y., Li, Q., Zeng, C., Fu, F., Guo, A., Zhang, H., Zou, P., Zhong, Z., Wang, H., et al. (2014) · Leukemia · doi:10.1038/leu.2014.51 · Cited by 68
Dinardo, C. D., Patel, K. P., Garcia‐Manero, G., Luthra, R., Pierce, S. A., Borthakur, G. M., Jabbour, E. J., Kadia, T. M., Pemmaraju, N., Konopleva, M. Y., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.855309 · Cited by 72
Khurshed, M., Molenaar, R. J., Lenting, K., Leenders, W. P. J., & Noorden, C. J. F. V. (2017) · Oncotarget · doi:10.18632/oncotarget.17106 · Cited by 72
Fei, D. L., Zhen, T., Durham, B. H., Ferrarone, J. R., Zhang, T., Garrett, L. J., Yoshimi, A., Abdel-Wahab, O. I., Bradley, R. K., Liu, P., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812669115 · Cited by 72
Self-citationCruickshanks, H. A., Vafadar-Isfahani, N., Dunican, D. S., Lee, A., Sproul, D., Lund, J. N., Meehan, R. R., & Tufarelli, C. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt438 · Cited by 70
Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions
Kim, T. K., Gore, S. D., & Zeidan, A. M. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.04.003 · Cited by 67
Chaudry, S. F., & Chevassut, T. J. T. (2017) · BioMed Research International · doi:10.1155/2017/5473197 · Cited by 69
Kirtonia, A., Pandya, G., Sethi, G., Pandey, A. K., Das, B. C., & Garg, M. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01944-5 · Cited by 68
Metadata
- Authors
- Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., Tallman, M. S., Sun, Z., Wolniak, K., Peeters, J. K., Liu, W., Choe, S. E., Fantin, V. R., Paietta, E., Löwenberg, B., Licht, J. D., Godley, L. A., Delwel, R., Valk, P. J. M., Thompson, C. B., Levine, R. L., & Melnick, A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Abramson Cancer Center (US)
- Weill Cornell Medicine (US)
- University of Chicago (US)
- Moffitt Cancer Center (US)
- Harvard University (US)
- Northwestern University (US)
- Erasmus MC (NL)
- Agios Pharmaceuticals (United States) (US)
- Montefiore Medical Center (US)
- Corresponding author
- Thompson, Craig B.
- Levine, Ross L.
- Melnick, Ari
- ORCID
- Abdel-Wahab, Omar
- Ward, Patrick S.
- Patel, Jay
- Shih, Alan
- Li, Yushan
- Bhagwat, Neha
- Vasanthakumar, Aparna
- Fernandez, Hugo F.
- Tallman, Martin S.
- Sun, Zhuoxin
- Wolniak, Kristy
- Liu, Wei
- Choe, Sung E.
- Fantin, Valeria R.
- Paietta, Elisabeth
- Löwenberg, Bob
- Licht, Jonathan D.
- Godley, Lucy A.
- Delwel, Ruud
- Valk, Peter J.M.
- Thompson, Craig B.
- Levine, Ross L.
- Melnick, Ari
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 18
- Issue
- 6
- Pages
- 553-567
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC4105845
- OpenAlex
- W2078972833
- Cited by
- 2,766
- References
- 35
- Citations by year
- 2026: 92 · 2025: 114 · 2024: 156 · 2023: 158 · 2022: 155 · 2021: 213 · 2020: 183 · 2019: 165 · 2018: 178 · 2017: 196 · 2016: 186 · 2015: 193 · 2014: 217 · 2013: 214 · 2012: 191
- FWCI
- 111.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- University of Pennsylvania
- Agios Pharmaceuticals
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL082950)
- National Cancer Institute (CA114737, R01CA105463, U54CA143798, U24CA114737, R01CA173636, U10CA021115, CA 21115)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, IDH2 mutation, acute myeloid leukemia, DNA hypermethylation, 2-hydroxyglutarate, TET2, hematopoietic differentiation, epigenetic dysregulation, stem/progenitor cells
- MeSH terms
- MDS1 and EVI1 Complex Locus Protein, Cell Differentiation, DNA-Binding Proteins, Humans, Hydroxylation, Isocitrate Dehydrogenase, Mutation, Phenotype, Proto-Oncogene Proteins, Proto-Oncogenes, Transcription Factors, Leukemia, Myeloid, Acute, DNA Methylation, Myeloid Cells, 5-Methylcytosine, Dioxygenases, GATA1 Transcription Factor, Gene Regulatory Networks
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
